Carbachol

Sold as Miostat. Every FDA application for this active ingredient: 1 branded and 2 generic.

As of Nov 13, 2026, FDA lists 3 applications for Carbachol (sold as Miostat), first approved Sep 28, 1972, with 1 new use approved and 0 published complete response letters.

First approved: Sep 28, 1972
Applications: 3
New uses approved: 1
Complete response letters: 0

Clinical Trials

1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all

Study	Phase	Status	Posted
Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia PatientsPresbyopia · Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Phase 2	Recruiting	Apr 29, 2025

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Sep 28, 1972	MiostatNDA 16968 · New molecular entity	Alcon	20	Marketed
Apr 28, 1995	CarbastatANDA 73677	Novartis	3	Discontinued
—	CarbacholANDA 70292	Pharmafair	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA